Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4624876 | 0.70 | — | — | |
| SCHEMBL31550503 | 0.70 | — | — | |
| SCHEMBL277412 | 0.70 | — | — | |
| Bromide SCHEMBL28518015 | 0.68 | SIGMAR1 (0.40) | SIGMAR1CHRNB2CHRNA4 | |
| Hydrochloric Acid SCHEMBL28011824 | 0.68 | SIGMAR1 (0.40) | SIGMAR1CHRNB2CHRNA4 | |
| SCHEMBL30423355 | 0.68 | SIGMAR1 (0.40) | SIGMAR1CHRNB2CHRNA4 | |
| SCHEMBL72253 | 0.67 | — | — | |
| SCHEMBL1950016 | 0.67 | SIGMAR1 (0.43) | SIGMAR1CHRNB2CHRNA4 | |
| SCHEMBL31281120 | 0.67 | — | — | |
| SCHEMBL24592280 | 0.65 | CYP11B2 (0.49) | SIGMAR1CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060116368-A1 | 4-Piperidinecarboxamide modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-01 | — | — | US | disclosed |
| WO-2006058338-A2 | 4 - PIPERIDINECARBOXAMIDE DERIVATIVES AS MODULATORS OF VANILLOID VR1 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116368-A1 | 4-Piperidinecarboxamide modulators of vanilloid VR1 receptor | VDAC1, TRPV1, HVCN1 | SIGMAR1 197/4885CHRNB2 1088/4885CHRNA4 388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.